Shares of other companies:
Microsoft Is Going To Win The AI War
May 31, 2024
Tesla: 7 Reasons To Short The Stock
May 31, 2024
Amazon Is Way Too Cheap
May 31, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
IMMX Stock News and Mentions of Immix Biopharma, Inc. Stocktwits
Updated: June 2, 2024 (15:26)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Immix Biopharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Immix Biopharma, Inc. (IMMX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Immix Biopharma stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Immix Biopharma, Inc. (IMMX)
May 13, 2024 (17:48) / "Benzinga" (by Dylan Berman)
Why MiNK Therapeutics Stock Is Up 11% Monday - MiNK Therapeutics ( NASDAQ:INKT )
MiNK Therapeutics, Inc. INKT shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. What Happened: On Monday, MiNK Therapeutics entered into a stock purchase agreement to sell securities in a private investment in ...
In Article Trend: Somewhat-Bullish
May 13, 2024 (11:30) / "Benzinga" (by Globe Newswire)
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer - MiNK Therapeutics ( NASDAQ:INKT )
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKT GKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 ( GLOBE NEWSWIRE ) -- MiNK Therapeutics, Inc.
In Article Trend: Neutral
May 10, 2024 (13:35) / "Benzinga" (by Globe Newswire)
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation - Immix Biopharma ( NASDAQ:IMMX )
92% ( 12/13 ) overall response rate ( ORR ) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 ( 100% ORR ) , of which 9 out of 12 were complete responders ( 75% CRs )
In Article Trend: Neutral
May 10, 2024 (13:35) / "GlobeNewswire" (by Inc.)
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% ( 12/13 ) overall response rate ( ORR ) for relapsed/refractory AL Amyloidosis patients enrolled in ...
In Article Trend: Neutral
April 29, 2024 (13:39) / "GlobeNewswire" (by Immix Biopharma)
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation ( "ODD" ) qualifies NXC-201 for: ...
In Article Trend: Neutral
April 18, 2024 (13:32) / "GlobeNewswire" (by Inc.)
Immix Biopharma on Track to Dose NXC-201 Patients in United States
• Scheduling U.S. site initiation visits April and May 2024 • On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024
In Article Trend: Neutral
April 15, 2024 (13:36) / "GlobeNewswire" (by Inc.)
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT )
LOS ANGELES, April 15, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc. ( Nasdaq: IMMX ) ( "ImmixBio", "Company", "We" or "Us" or "IMMX" ) , a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated ...
In Article Trend: Neutral
April 15, 2024 (13:36) / "Benzinga" (by Globe Newswire)
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT ) - Immix Biopharma ( NASDAQ:IMMX )
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website